Basic Information
| LncRNA/CircRNA Name | GAPLINC |
| Synonyms | NA |
| Region | GRCh38_18:3466250-3478978 |
| Ensemble | ENSG00000266835 |
| Refseq | NR_110429 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | NSCLC tissues, NSCLC cell lines (LTEP-A2, NCI-H1299, SK-MES-1, and Calu-3),The normal human bronchial epithelial cell line (NHBE) and HEK- 293T |
| Expression Pattern | up-regulated |
| Function Description | GAPLINC expression was up-regulated in NSCLC tissues and cell lines. Overexpression of GAPLINC was associated with poor prognosis in patients with NSCLC. Silencing of GAPLINC significantly inhibited cell proliferation, promoted apoptosis, and induced cell cycle arrest in the G0/G1 phase. Results from xenograft transplantation showed that GAPLINC silencing inhibited the tumor growth in vivo. Interestingly, GAPLINC silencing decreased the expression of eukaryotic elongation factor-2 kinase (eEF2K) protein both in vivo and in vitro. Bioinformatic analysis and luciferase reporter confirmed that miR-661 targeted GAPLINC and eEF2K 3 -UTR and was negatively correlated with the expression of GAPLINC and eEF2K. C |
| Pubmed ID | 30522114 |
| Year | 2018 |
| Title | Gastric Adenocarcinoma Predictive Long Intergenic Non-Coding RNA Promotes Tumor Occurrence and Progression in NonSmall Cell Lung Cancer via Regulation of the miR-661/eEF2K Signaling Pathway |
External Links
| Links for GAPLINC | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |